Latest glioblastoma multiforme Stories
SYDNEY, Aug. 13, 2014 /PRNewswire/ -- Australia-US biotechnology company, Novogen Ltd.
SAN FRANCISCO, Aug.
Trial Progressing On Track; BETHESDA, Md., Aug.
Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered. BETHESDA, Md., Aug.
Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates.
NuvOx Pharma, a Tucson based biotechnology company, began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer. Tucson,
POINT ROBERTS, Wash. and NEW YORK, Aug.
New research at Washington University School of Medicine in St. Louis helps explain why brain tumors occur more often in males and frequently are more harmful than similar tumors in females.
- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill., Aug.
National Brain Tumor Society connects biotech company to researchers’ technology. Hershey, PA & Boston, MA (PRWEB) July 28, 2014 Immunomic Therapeutics,
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.